A Phase 3, Randomized, Multicenter, Single-blind, Controlled Study Evaluating Arteriovenous Fistula Outcomes With and Without a Perivascular Sirolimus-Eluting Collagen Implant
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Arteriovenous fistula
- Focus Therapeutic Use
- Acronyms ACCESS
- Sponsors Vascular Therapies
- 09 Sep 2019 Results presented in a Vascular Therapies Media Release.
- 09 Sep 2019 According to a Vascular Therapies media release, preliminary results were presented at Eastern Vascular Society Meeting in Pittsburg, Pennsylvania.
- 09 Sep 2019 According to a Vascular Therapies media release,the 6-month primary endpoint (Fistula Suitability for Dialysis at 6 Months) results are expected to be announced in the second quarter of 2020.